Choosing the right serum and molecular biomarkers in the Philippines

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC

Neoadjuvant nivolumab plus chemotherapy continues to provide long-term clinical benefit in patients with resectable NSCLC

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC

LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC

CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC

Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1 inhibitors resistant second line metastatic NSCLC

Assessment of QoL results and correlation with survival outcomes in phase III clinical trials in metastatic NSCLC

PSMO and the future of cancer care in the Philippines

Low value practices that result in poor patient outcomes in LMICs

Key methods for handling difficult conversations in cancer care

Tumour markers and their role in cancer treatment